|
1
|
Ohgaki H and Kleihues P: The definition of
primary and secondary glioblastoma. Clin Cancer Res. 19:764–772.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae
JA, Yoon S, Ryu HH, Jung S, Kim KK, et al: KITENIN promotes glioma
invasiveness and progression, associated with the induction of EMT
and stemness markers. Oncotarget. 6:3240–3253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and
Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q,
Ding J, Jia Y, Chen Z, Li L, et al: Tet-mediated formation of
5-carboxylcytosine and its excision by TDG in mammalian DNA.
Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito S, Shen L, Dai Q, Wu SC, Collins LB,
Swenberg JA, He C and Zhang Y: Tet proteins can convert
5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine.
Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pastor WA, Aravind L and Rao A: TETonic
shift: Biological roles of TET proteins in DNA demethylation and
transcription. Nat Rev Mol Cell Biol. 14:341–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dawlaty MM, Breiling A, Le T, Raddatz G,
Barrasa MI, Cheng AW, Gao Q, Powell BE, Li Z, Xu M, et al: Combined
deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is
compatible with postnatal development. Dev Cell. 24:310–323. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ko M, Bandukwala HS, An J, Lamperti ED,
Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB and
Rao A: Ten-Eleven-Translocation 2 (TET2) negatively regulates
homeostasis and differentiation of hematopoietic stem cells in
mice. Proc Natl Acad Sci USA. 108:14566–14571. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Costa Y, Ding J, Theunissen TW, Faiola F,
Hore TA, Shliaha PV, Fidalgo M, Saunders A, Lawrence M, Dietmann S,
et al: NANOG-dependent function of TET1 and TET2 in establishment
of pluripotency. Nature. 495:370–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quivoron C, Couronné L, Della Valle V,
Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F,
Arnulf B, Stern MH, et al: TET2 inactivation results in pleiotropic
hematopoietic abnormalities in mouse and is a recurrent event
during human lymphomagenesis. Cancer Cell. 20:25–38. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delhommeau F, Dupont S, Della Valle V,
James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F,
Alberdi A, et al: Mutation in TET2 in myeloid cancers. N Engl J
Med. 360:2289–2301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv
L, Wang P, Yang H, Ma S, Lin H, et al: WT1 recruits TET2 to
regulate its target gene expression and suppress leukemia cell
proliferation. Mol Cell. 57:662–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Z, Chen L, Dawlaty MM, Pan F, Weeks
O, Zhou Y, Cao Z, Shi H, Wang J, Lin L, et al: Combined Loss of
Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in
Mice. Cell Rep. 13:1692–1704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takayama K, Misawa A, Suzuki T, Takagi K,
Hayashizaki Y, Fujimura T, Homma Y, Takahashi S, Urano T and Inoue
S: TET2 repression by androgen hormone regulates global
hydroxymethylation status and prostate cancer progression. Nat
Commun. 6:82192015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dzitoyeva S, Chen H and Manev H: Effect of
aging on 5-hydroxymethylcytosine in brain mitochondria. Neurobiol
Aging. 33:2881–2891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hahn MA, Qiu R, Wu X, Li AX, Zhang H, Wang
J, Jui J, Jin SG, Jiang Y, Pfeifer GP and Lu Q: Dynamics of
5-hydroxymethylcytosine and chromatin marks in Mammalian
neurogenesis. Cell Rep. 3:291–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Branco MR, Ficz G and Reik W: Uncovering
the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev
Genet. 13:7–13. 2011.PubMed/NCBI
|
|
21
|
Spruijt CG, Gnerlich F, Smits AH,
Pfaffeneder T, Jansen PW, Bauer C, Münzel M, Wagner M, Müller M,
Khan F, et al: Dynamic readers for 5-(hydroxy)methylcytosine and
its oxidized derivatives. Cell. 152:1146–1159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko M, Huang Y, Jankowska AM, Pape UJ,
Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R,
et al: Impaired hydroxylation of 5-methylcytosine in myeloid
cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Solary E, Bernard OA, Tefferi A, Fuks F
and Vainchenker W: The Ten-Eleven Translocation-2 (TET2) gene in
hematopoiesis and hematopoietic diseases. Leukemia. 28:485–496.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kraus TF, Globisch D, Wagner M, Eigenbrod
S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden
W, et al: Low values of 5-hydroxymethylcytosine (5hmC), the ‘sixth
base,’ are associated with anaplasia in human brain tumors. Int J
Cancer. 131:1577–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kraus TF, Greiner A, Steinmaurer M,
Dietinger V, Guibourt V and Kretzschmar HA: Genetic
characterization of ten-eleven-translocation methylcytosine
dioxygenase alterations in human glioma. J Cancer. 6:832–842. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li
X, Zhao D, Liu Y, Wang C, Zhang X, et al: Tet2 is required to
resolve inflammation by recruiting Hdac2 to specifically repress
IL-6. Nature. 525:389–393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim YH, Pierscianek D, Mittelbronn M,
Vital A, Mariani L, Hasselblatt M and Ohgaki H: TET2 promoter
methylation in low-grade diffuse gliomas lacking IDH1/2 mutations.
J Clin Pathol. 64:850–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edwards LA, Woolard K, Son MJ, Li A, Lee
J, Ene C, Mantey SA, Maric D, Song H, Belova G, et al: Effect of
brain- and tumor-derived connective tissue growth factor on glioma
invasion. J Natl Cancer Inst. 103:1162–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
